Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quince Therapeutics Inc QNCX

Healthcare Biotechnology
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s... see more

Recent & Breaking News (NDAQ:QNCX)

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Business Wire September 16, 2022

Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

Business Wire September 12, 2022

Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Business Wire August 30, 2022

Quince Therapeutics to Present at Upcoming Scientific Meetings

Business Wire August 25, 2022

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022

Business Wire August 4, 2022

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

Business Wire July 27, 2022

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Business Wire July 27, 2022

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Business Wire June 21, 2022

Cortexyme Appoints June Bray to its Board of Directors

Business Wire June 13, 2022

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

Business Wire May 20, 2022

Cortexyme Successfully Completes Acquisition of Novosteo

Business Wire May 20, 2022

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Business Wire May 12, 2022

Cortexyme Announces Agreement to Acquire Novosteo

Business Wire May 10, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

PR Newswire April 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX

Newsfile April 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

PR Newswire April 11, 2022

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTX

Business Wire April 5, 2022

CRTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm

Newsfile March 23, 2022

CRTX SHAREHOLDER ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

Newsfile March 21, 2022

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile March 21, 2022